Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi Invests $30M in Gene Therapy Company MeiraGTx | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sanofi Invests $30M in Gene Therapy Company MeiraGTx

Sanofi receives right of first negotiation to use MeiraGTx’s Riboswitch gene regulation technology for certain immunology, CNS, and metabolic targets.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi has made a $30 million strategic investment in MeiraGTx Holdings plc, a clinical stage gene therapy company, through the purchase of 4 million ordinary shares.

Sanofi receives right of first negotiation to use MeiraGTx’s Riboswitch gene regulation technology for certain immunology, inflammation, and CNS targets, GLP-1 and other gut peptides for metabolic disease, and for MeiraGTx’s Phase 2 Xerostomia program.

Riboswitch is a short sequence of DNA that can be added to a gene therapy that can be toggled on and off with an oral pill to precisely control when and how much of the gene therapy gets made. The company has generated encouraging preclinical data demonstrating the ability to control the production of antibodies, gut peptides, hormones, and a range of other molecules. 

“We are very pleased with this first strategic investment from Sanofi,” said Alexandria Forbes, President, and CEO of MeiraGTx. “We view Sanofi’s interest in our Riboswitch gene regulation technology and our clinical Xerostomia program as further validation of the broad potential of our vertically integrated platform and we are excited to work with Sanofi as we advance these programs.”

Paul Hudson, CEO of Sanofi, said, “Our mission at Sanofi is to deliver first or best in class medicines and vaccines for patients. So, we welcome technological innovations that help us chase the scientific miracles of the future. We believe that MeiraGTx’s Riboswitch platform, supported by its unique manufacturing capabilities, is such a technology. We look forward to working alongside MeiraGTx as this innovative science moves forward to create a new generation of breakthrough medicines for immune-mediated and neurological diseases.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics